NEWS / IR
-
Dec 21, 2023
인큐릭스, 제3회 ‘코어 스타트업 어워즈’ 전국부문 최우수상 수상
View More
-
Dec 14, 2023
인큐릭스, '경기중기청 스타트업 815 IR' 중기부 장관상 수상
View More
-
Dec 07, 2023
인큐릭스 (INCUXRIX), Myc전사인자 표적 치료제 ‘ICX-130’ “KDDF 과제 선정”
View More
-
Nov 03, 2023
인큐릭스, 2023 'IP 기반 창업기업 통합 투자유치설명회'서 우수상 수상
View More
-
Oct 24, 2023
[KDB Next Round] Round 706 특허청/발명진흥회 IR 참가
View More
-
Sep 22, 2023
인큐릭스, 전립선암 표적 치료제 'ICX-301' KDDF 과제 선정
View More
-
April 25, 2023
인큐릭스, ‘MYC 저해제’ 초기연구 “AACR 발표”
View More
-
April 18, 2023
Incurix's MYC inhibitor emerges as first-line therapy option for lung cancer patients: Presented at AACR
View More
-
April 25, 2022
The website has been completed and opened.
View More
-
Feb 21, 2022
Incurix signs agreement with AIGEN Sciences for joint development on AI-based Transcription Factor inhibitor
View More
-
June 30, 2021
Incurix secures license of ‘STAT3 inhibitor anti-cancer drug’ from NCC and KRICT
View More
-
Nov 19, 2020
National OncoVenture and FEBPS host joint online symposium
View More
-
Sep 10, 2020
Incurix makes an agreement with National OncoVenture for cooperation in Research and Development
View More
-
April 28. 2020
Incurix introduces ‘c-myc inhibitor anti-cancer drug’ technology from the National Cancer Center
View More
-
Dec 18, 2018
Incurix established as an in-house venture of the National Cancer Center
View More
- 6F, 1072, Jungang-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10447, Republic of Korea
- +82-31-907-3131
- office@incurix.com
COPYRIGHT © INCURIX.CO.,LTD. ALL RIGHTS RESERVED.
